SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Hubert H. Humphrey

PatientHubert H. Humphrey
Date of birth1960-05-27
IdentifiersMRN HR-ML022-SYN; SSN (made up) 000-22-8047
Document date2026-04-07
AuthorWalter Brandvold, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month follow-up after cystectomy; review after a kidney infection. [S]

History of Present Illness

Mr. Humphrey returns two months after his last visit, six months after his operation and three weeks after the sick visit for a right kidney infection. The culture grew Escherichia coli susceptible to ciprofloxacin; his fever settled within 48 hours, and he finished the 7-day course. The creatinine recheck planned for one week after that visit was not done, because he was travelling for work. He now drinks about 2 liters a day. Since the new convex wafer he has had no leaks, and the skin below the stoma has healed. Over the past month he has felt more tired by late afternoon, without breathlessness, and his appetite is good. He had a renal ultrasound this morning. He walks 30 minutes most days. [S]

ElementDetail
InfectionEscherichia coli pyelonephritis three weeks ago, resolved on ciprofloxacin
StomaNo leaks since the refit two months ago; skin healed
SymptomsLate-afternoon tiredness for a month
ImagingRenal ultrasound this morning

Review of Systems

SystemResultFinding
ConstitutionalPositiveLate-afternoon tiredness; no fever; weight up
GenitourinaryNegativeClear urine; no flank pain
IntegumentaryNegativePeristomal skin comfortable
RespiratoryNegativeNo breathlessness or cough
PsychiatricNegativeMood good; PHQ-2 score 1

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sodium bicarbonate 650 mg oral tablet, one tablet by mouth twice daily, for metabolic acidosis after an ileal conduitOne tablet twice dailyOral route2026-04-07activeS
Ciprofloxacin 500 mg oral tablet, one tablet by mouth twice daily for 7 days, for acute pyelonephritisOne tablet twice daily for 7 daysOral route2026-03-17 to 2026-03-23completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-07Body height180cmS
2026-04-07Body weight77.6kgS
2026-04-07Body mass index (BMI) [Ratio]24kg/m2S
2026-04-07Systolic blood pressure126mm[Hg]S
2026-04-07Diastolic blood pressure74mm[Hg]S
2026-04-07Heart rate70/minS
2026-04-07Respiratory rate14/minS
2026-04-07Body temperature36.6CelS
2026-04-07Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-07Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-04-07Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-04-07Chloride [Moles/volume] in Serum or Plasma110mmol/L98-107 mmol/LHighS
2026-04-07Carbon dioxide, total [Moles/volume] in Serum or Plasma20mmol/L22-29 mmol/LLowS
2026-04-07Urea nitrogen [Mass/volume] in Serum or Plasma16mg/dL8-23 mg/dLNormalS
2026-04-07Creatinine [Mass/volume] in Serum or Plasma1.15mg/dL0.74-1.35 mg/dLNormalS
2026-04-07Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M71mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-07Hemoglobin [Mass/volume] in Blood13.4g/dL13.2-16.6 g/dLNormalS
2026-04-07Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Physical Exam

Vital signs recorded on 2026-04-07; see the Vital Signs section. [S]

SystemFinding
GeneralWell
AbdomenSoft; no flank or costovertebral angle tenderness; no hernia
StomaPink and moist; peristomal skin healed; convex wafer sealing well
RespiratoryRespiratory rate 14; clear

Problems

ProblemClinical statusVerificationCodeProvenance
Urothelial carcinoma of the bladder, multifocal, with carcinoma in situ, pT2a pN0 (0 of 18 nodes), margins negative, treated by radical cystoprostatectomy with an ileal conduit; no evidence of disease; under surveillance; synthetic modern detail linked to his documented bladder canceractiveconfirmed Z85.51S — Synthetic grade, stage, node count, and margins; the bladder growths, the earlier thiotepa and X-ray therapy, the low-grade malignancy, and the radical cystectomy with a small-intestine conduit are documented (D). Z85.51 is used because the tumor has been removed and no further treatment is directed at it.
Ileal conduit urostomy, right lower abdomenactiveconfirmed Z93.6S — The small-intestine conduit and the stoma to the right of the navel are documented (D); the coding and the stoma findings are synthetic.
Acquired absence of the bladder and part of the urethra after radical cystectomyactiveconfirmed Z90.6S — Documented operation (D); synthetic coding.
Acquired absence of the prostate after cystoprostatectomyactiveconfirmed Z90.79S — Documented operation (D); synthetic coding.
Personal history of pelvic radiation for bladder tumor, with earlier intravesical thiotepaactiveconfirmed Z92.3S — The thiotepa and X-ray therapy are documented (D); the coding and their relevance to the modern episode are synthetic.
Hyperchloremic metabolic acidosis from the ileal conduit, mildactiveconfirmed E87.22S — Synthetic finding at the six-month visit, a known effect of urine contact with the ileal segment.
Acute right pyelonephritis with an ileal conduit (Escherichia coli), with mild acute kidney injury, treated with oral ciprofloxacin and resolvedresolvedconfirmed N10S — Synthetic intercurrent infection at an unscheduled visit, a common complication of an ileal conduit; it does not echo a documented illness of his after the operation.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryChemistry with creatinine, chloride, and bicarbonateEvery 3 to 6 months in the first year after diversion, then yearlyCompleted todayCreatinine 1.15 mg/dL, eGFR 71; chloride 110 and bicarbonate 20 mmol/L (low): hyperchloremic acidosis; treatment started
LaboratoryCreatinine one week after acute kidney injuryOne week after the sick visitDeferredNot done, a deviation from the plan made at the sick visit; he was travelling. Today's creatinine of 1.15 mg/dL is near the baseline of 1.12, so the kidney injury resolved and no harm resulted. Corrective action: post-illness rechecks are now booked before he leaves the clinic, with a reminder call
LaboratoryHemoglobinAfter major surgery until recoveredCompleted today13.4 g/dL, recovered from 12.6
LaboratoryVitamin B12Yearly from two to three years after an ileal diversionUp to dateBaseline normal three months ago
ImagingUpper-tract imaging (renal ultrasound or CT urography)Every 6 months to year 3, then yearlyCompleted todayRenal ultrasound: no hydronephrosis on either side; normal kidneys
ImagingCT of the chest, abdomen, and pelvis (with urographic phase)Every 6 to 12 months for 2 to 3 years after cystectomy, then yearlyDueAt one year after surgery, in six months
ExaminationStoma and peristomal skinEvery visitCompleted todaySkin healed; no leaks since the refit two months ago
ExaminationParastomal and incisional herniaEvery visitCompleted todayNone
SurveyDistress and depression screen (PHQ-2)Every visitCompleted todayPHQ-2 score 1
LaboratoryRoutine urine culture of conduit urineOnly for fever, flank pain, or other signs of infectionNot indicatedBacteria are expected in conduit urine; no symptoms today
LaboratoryUrethral wash cytologyPeriodically if the urethra is retained and at high riskNot indicatedUrethral margin negative and no prostatic urethral involvement
Self-managementFluid intakeEvery visitCompleted todayAbout 2 liters a day since the infection

Goal progress:

Guideline basis: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); Trautner BW, et al. IDSA 2025 Guideline Update on Complicated Urinary Tract Infections (2025); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026)

Follow-up: Annual wellness visit in eight weeks. Primary care in three months with chemistry on sodium bicarbonate. Next scheduled visit 2026-06-02: subsequent annual wellness visit. [S]